CD20 x CD3
Assets acting on this target.
- Class
- T-cell engaging bispecific antibody
- Pathway
- CD8/TCR-based T-cell engager bridging CD3+ T cells to CD20+ B cells for B-cell depletion
CD20 x CD3 bispecific antibodies are engineered to bind two different targets at once: CD20, a protein found on the surface of B lymphocytes (including malignant B cells in many lymphomas and leukemias), and CD3, part of the receptor complex present on nearly all T cells. By attaching to both cell types simultaneously, the antibody physically links a T cell to a B cell, creating a forced contact point called an immune synapse. This contact activates the T cell and triggers it to kill the attached B cell, regardless of what antigen that T cell would normally recognize. The biological rationale is to redirect a patient's existing T-cell population toward malignant or otherwise unwanted B cells without requiring prior immune priming against a tumor-specific antigen. This mechanism is broadly relevant in B-cell cancers, such as non-Hodgkin lymphomas and certain leukemias, where CD20 is consistently and stably expressed, and in some autoimmune diseases driven by pathogenic B cells. Compared with an antibody that targets CD20 alone, adding a CD3-binding arm converts B-cell elimination from a passive process, dependent on complement or natural killer cells, into an active, T-cell-driven killing mechanism that can operate even where those other effector systems are weak.
By indication
Related mechanisms
CD20 x CD3 drugs compared
5 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Epcoritamab | AbbVie, Genmab | bispecific antibody | Approved | Approved in Diffuse Large B-Cell Lymphoma; Approved in Follicular Lymphoma; Approved in High-Grade B-Cell Lymphoma; Approved in Large B-Cell Lymphoma |
| Odronextamab | Regeneron Pharmaceuticals | bispecific antibody | Phase 3 | Phase 3 in B-Cell Non-Hodgkin Lymphoma; Phase 3 in Diffuse Large B-Cell Lymphoma; Phase 3 in Follicular Lymphoma; Phase 1 in Systemic Lupus Erythematosus |
| AZD5492 | AstraZeneca | bispecific antibody (trispecific T-cell engager) | Phase 1/2 | Phase 1 in Rheumatoid Arthritis; Phase 1 in Systemic Lupus Erythematosus |
| CND261 | Candid Therapeutics, UCB | biologic (registry-typed, subtype undisclosed) | Phase 1 | Phase 1 in Rheumatoid Arthritis |
| Plamotamab | Xencor | bispecific antibody | Phase 1 | Phase 1 in Rheumatoid Arthritis |